BioSpace News Archive

Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, today announced the details of its poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held from April 14 - 19, 2023 in Orlando, Florida.

Flare Therapeutics Inc. today announced that it will give an oral presentation highlighting the discovery of its clinical candidate FX-909, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the acceptance of eleven abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place at the Orange County Convention Center in Orlando, FL from April 14 – 19, 2023.

Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced it will be presenting two late-breaking abstracts during the American Association for Cancer Research (AACR) Annual Meeting to be held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida.

Sana Biotechnology, Inc. announced that four abstracts, including a late-breaking abstract, highlighting preclinical data from both the hypoimmune and fusogen platforms have been accepted for poster presentation at the 2023 American Association for Cancer Research Annual Meeting taking place April 14-19, 2023 in Orlando, FL.

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX) today announced the data from the Phase I/II trials evaluating camonsertib (RP-3500/RG6526, partnered with Roche) in combination with three poly (ADP-ribose) polymerase inhibitors (PARPi) has been selected for the clinical plenary session at the 2023 AACR Annual Meeting, held April 14-19, 2023, in Orlando, Florida.

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that two abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in Orlando from April 14-19, 2023.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), announced today that they will be participating in Renmark Financial Communications Inc. ‘s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, March 21, 2023, at 11:00 AM PST and Tuesday, March 28, 2023 at 10:00 AM EST.

Cyclica Inc. and the National Research and Innovation Agency announce a partnership leveraging Cyclica’s AI-enabled drug discovery platform to drive innovation within Uruguay’s biotech ecosystem.

Henry Schein, Inc. announced that it will showcase its comprehensive solutions and provide its perspective on the future of dentistry at the 2023 International Dental Show in Cologne, Germany.